Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Matrix Large Cap Value Strategy Matrix Asset Advisors, Inc. | “ABT is a diversified global healthcare company that operates across four primary business segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. We believe” | NEUTRAL | Q2 2026 Jul 30, 2026 | View Pitch |
Matrix Large Cap Value Strategy Matrix Asset Advisors, Inc. | “ABT is a diversified global healthcare company that operates across four primary business segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmace...” | BULL | Q2 2026 Jul 30, 2026 | View Pitch |
Alpha Wealth Funds - The Insiders Fund Portfolio Manager | “Abbott Laboratories is a global healthcare leader focused on life-changing technologies. Founded in 1888, the company operates across four primary segments: Diagnostics, Medical Devices, Established Pharmaceuticals, and Nutrition. Abbott is widely recognized for its Dividend King status, having increased its dividend for over 50 consecutive years. In late June 2026, the U.S. Department of Justice officially closed its criminal probe into Abbott's Sturgis, Michigan infant formula plant (tied to the 2022 bacterial contamination and nationwide shortages). The DOJ opted to pursue civil penalties under the False Claims Act instead. This removes a massive legal and criminal overhang that has suppressed the stock for years, offering investors much clearer visibility on Abbott's remaining legal liabilities. The purchase of Exact Sciences provides them a Grail-like MCED cancer diagnostic to test their already robust product line. Abbott Laboratories is a dividend king so whenever we have an opportunity to buy a blue chip confirmed by insider buying, it's almost an automatic buy. We are underwater by about 7% and have been adding to this position.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
“At the end of the day, it was always something with Abbott. Whether it was an inventory adjustment in China, a division every now and again that fell short of plan and required a leadership change or” | NEUTRAL | Q2 2026 Jul 15, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
